Explore the Knowledge Graph

Companies

9,600+ pipelines, each resolved to the company that owns it today

Coverage

  • 9,600+ company pipelines, from preclinical programs through clinical-stage trials.
  • Normalized companies from trial sponsors, product labellers, and name variants, resolved into one record per company.
  • 2,300+ parent-to-subsidiary chains resolved by engineering company hierarchies, with relationships labelled as an absorbed subsidiary, an independent subsidiary, or a merger.

Where it connects

Company record Pfizer 41 filed names resolve to Pfizer
Drugs Every asset the company owns, at every stage
namePalbociclib drugbank_idDB09073 approval_statusapproved, investigational +775 more assets
Clinical trials Every trial the company sponsors, under any of its names
trialNCT04993677 sponsors.title (as filed)Seagen Inc.absorbed subsidiary companies.namePfizer

5,467 trials rolling up to Pfizer, 1,164 of them filed under another company’s name

Targets The biology its portfolio acts on, through the drugs that bind it
drugBHV-7000 proteinPotassium voltage-gated channel subfamily KQT member 2 targetKCNQ2 uniprot_idO43526 modulation_typeactivation +102 more proteins across Pfizer’s programs
Diseases A portfolio’s therapeutic focus
indicationtinnitus conditionTinnitus, Spontaneous Oto-Acoustic Emission
drugbank_idDBCOND0068067 indication_kindtreatment_of disease_areasOtorhinolaryngologic Diseases +2 more disease areas

Zoom in

Sponsor names resolving under Pfizer
sponsors.titlecompanies.namerelationship_type
Seagen Inc.Seagenabsorbed_subsidiary
Wyeth is now a wholly owned subsidiary of PfizerWyethabsorbed_subsidiary
Pharmacia and UpjohnPharmaciaabsorbed_subsidiary
Biohaven Therapeutics Ltd.Biohavenabsorbed_subsidiary
Arena PharmaceuticalsArena Pharmaceuticalsindependent_subsidiary
King Pharmaceuticals is now a wholly owned subsidiary of PfizerKing Pharmaceuticalsmerger

+35 more names

Programs under Pfizer
program_drugbank_idnametargetindicationraw_status
DBPRG00156843opakalim for tinnitusPotassium voltage-gated channel subfamily KQT member 2Tinnitus, Spontaneous Oto-Acoustic Emissionactive
DBPRG00171171BHV-8200 for Parkinson's diseaseAlpha-synucleinParkinson's Disease (PD)active
DBPRG00154389BHV-1440 for Graves' diseaseThyrotropin receptorGraves Disease (Basedow's Disease)active
DBPRG00133641BHV-1420 for membranous nephropathySecretory phospholipase A2 receptorMembranous Nephropathyactive
DBPRG00172892[unnamed 35-valent pneumococcal vaccine candidate] for pneumococcal disease[]Pneumococcal Infection[]
DBPRG00061331[unnamed entity] for [unspecified condition]Tyrosine-protein kinase JAK1[]discontinued

+498 more programs

Events on Pfizer programs
program_drugbank_idcategorydate_kindraw_kindraw_dateevent_date
DBPRG00136749preclinical_milestoneactualPreclinical data presentationSeptember 10, 20242024-09-10
DBPRG00118331regulatory_submissionactualRegulatory interaction with FDAfirst half of 20252025-01-01
DBPRG00144090preclinical_milestoneactualIND-enabling studies initiated[]2025-03-26
DBPRG00067975business_decisionactualPreclinical development paused[]2024-11-12
DBPRG00090731clinical_milestoneanticipatedPhase 2 initiation2024[]
DBPRG00118298regulatory_submissionanticipatedIND submission2025[]

+199 more events

Pfizer’s development programs by indication
conditions.titledisease_areasprograms
Sickle Cell DiseaseHemic and Lymphatic Diseases; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiovascular Diseases36
Beta-ThalassemiaHemic and Lymphatic Diseases; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiovascular Diseases31
Malignant NeoplasmsNeoplasms20
Frontotemporal Lobar Degeneration (FTLD)Nutritional and Metabolic Diseases; Mental Disorders; Nervous System Diseases; Congenital, Hereditary, and Neonatal Diseases and Abnormalities18
Coronavirus Disease 2019 (COVID-19)Infections15
Immunoglobulin A NephropathyUrogenital Diseases; Immune System Diseases14
Inflammatory Bowel Diseases (IBD)Digestive System Diseases; Infections12
Parkinson's Disease (PD)Nutritional and Metabolic Diseases; Mental Disorders; Nervous System Diseases11

Questions it answers

  • Which of an acquirer’s pipelines overlap with ours? Landscape and whitespace analysis
  • What is a competitor working on before it reaches a trial registry? Competitive clinical landscape
  • Which deprioritized or divested assets in our area could be licensed? Landscape and whitespace analysis

All figures pulled as of November 2026.

Get answers you can trust, every time.